Stay updated on AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Sign up to get notified when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.

Latest updates to the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page
- Check3 days agoChange DetectedThe site footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check10 days agoChange DetectedThe error page has been replaced by the completed Phase 3 ATTRibute-CM study record, with details on the treatment and outcomes, eligibility, study locations, and supporting documents.SummaryDifference100%

- Check17 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check31 days agoChange DetectedAn NIH-wide notice about terminology changes appears above the 403 error page, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study record page is currently returning a 403 Forbidden error, blocking access to the study details and related information on the page. Users cannot view documents, locations, or other study data.SummaryDifference18%

Stay in the know with updates to AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.